1.The Diagnostic Value of the Nitroblue Tetrazolium Dye Reduction Test in Orthopaedic Field
Key Yong KIM ; Duk Yun CHO ; Jang Kyu PARK ; Byoung Soo PARK ; Myoung Jun CHO
The Journal of the Korean Orthopaedic Association 1976;11(1):98-103
Nitroblue tetrazolium dye reduction test is now widely used for early detection of bacterial infection. Practically nitroblue tetrazolium dye reduction test (N.B.T. test) gives certain clue to rule out any possibility of aseptic inflammation. Authors performed N.B.T. test for 80 orthopaedic diseases and 40 controls, and the results were as followings: 1. Forty-one of 60 subjects with bacterial infection had more than 10% formazan positive neutrophils, and 18 of 20 subjects without bacterial infection showed less than 10%. formazan positive neutrophils, The groups of the elevated N.B.T. responses were mainly the subjects who had osteomyelitis, soft tissue inflammation, pyogenic arthritis, and bone and joint tuberculosis. 2. The mean proportion of N.B.T. positive neutrophils was 3.8±2.78% in 40 controls, 4.7±4.23% in 20 nonifectious group 12.7±10.3% in 12 chronic osteomyelitis, 12.5±10.7% in 15 treated bone and joint tuberculosis, 20.9±15.65% in 15 untreated bone and joint tuberculosis and 20±10.70% in 11 pyogenic arthritis and 7 other soft inflammatory group. 3. In noninfectious group, 7 of 8 subjects with elevated ESR and 3 of 4 subjects with elevated body temperature revealed N.B.T. responses less than 10%. 4. In 23 subjects with the elevated N.B.T. responses as well as leukecytosis, 22 subjects were the groups of bacterial infection and rest 1 was noninfectious in nature. 5. Therefore, the N.B.T. test is found to be useful for the purposes of the early diagnostic aid of the bacterial infection and differential diagnosis between bacterial infections and other diseases.
Arthritis
;
Bacterial Infections
;
Body Temperature
;
Diagnosis, Differential
;
Inflammation
;
Neutrophils
;
Nitroblue Tetrazolium
;
Osteomyelitis
;
Tuberculosis, Osteoarticular
2.A Case of Leiomyoblastoma of Stomach.
Sang Pal LEE ; Duk Key JANG ; Yong Jun HUR ; Young Ki CHUNG ; Dae Sik WON ; Dong Ryong SEO ; Doo Bok PAK
Korean Journal of Gastrointestinal Endoscopy 1988;8(2):141-144
In 1960 Martin and his associates described another type of tumor of the stomach derived from the smooth muscle, which they named myoid tumor in a study of six patients. In 1962 Stout applied the term "lelomyoblastoma" to this interesting entity in a report of a collected series of 69 patients. Tumor cells are round or polygonal epithelioid cells, which contain perinuclear vacuole or clear zone. A 58 year-old female was admitted to this hospital because of epigastric discomfort for three months. At Upper gastrointestinal series and gastrofiberscope, a round hemispherical submucosal tumor was noted at posterior wall near the lesser curvature of gastric antrum. After subtotal gastrectomy, the submucosal tumor was diagnosed as leiomyoblastoma. Because leiomyoblastoma are rare and easily misdiagnosed as leiomyoma or leiomyosarcoma, careful histologic study is recommended.
Epithelioid Cells
;
Female
;
Gastrectomy
;
Humans
;
Leiomyoma
;
Leiomyoma, Epithelioid*
;
Leiomyosarcoma
;
Middle Aged
;
Muscle, Smooth
;
Pyloric Antrum
;
Stomach*
;
Vacuoles
3.Erratum to: Prognosis of Patients with Behavioral Variant Frontotemporal Dementia Who have Focal Versus Diffuse Frontal Atrophy.
Jin San LEE ; Na Yeon JUNG ; Young Kyoung JANG ; Hee Jin KIM ; Sang Won SEO ; Juyoun LEE ; Yeo Jin KIM ; Jae Hong LEE ; Byeong C KIM ; Kyung Won PARK ; Soo Jin YOON ; Jee H JEONG ; Sang Yun KIM ; Seung Hyun KIM ; Eun Joo KIM ; Key Chung PARK ; David S KNOPMAN ; Duk L NA
Journal of Clinical Neurology 2017;13(4):447-447
The original version of this article contained wrong information of an author which should be changed.
4.Prognosis of Patients with Behavioral Variant Frontotemporal Dementia Who have Focal Versus Diffuse Frontal Atrophy.
Jin San LEE ; Na Yeon JUNG ; Young Kyoung JANG ; Hee Jin KIM ; Sang Won SEO ; Juyoun LEE ; Yeo Jin KIM ; Jae Hong LEE ; Byeong C KIM ; Kyung Won PARK ; Soo Jin YOON ; Jee H JEONG ; Sang Yun KIM ; Seung Hyun KIM ; Eun Joo KIM ; Key Chung PARK ; David S KNOPMAN ; Duk L NA
Journal of Clinical Neurology 2017;13(3):234-242
BACKGROUND AND PURPOSE: Only a few studies have investigated the relationship between different subtypes and disease progression or prognosis in patients with behavioral variant frontotemporal dementia (bvFTD). Since a localized injury often produces more focal signs than a diffuse injury, we hypothesized that the clinical characteristics differ between patients with bvFTD who show diffuse frontal lobe atrophy (D-type) on axial magnetic resonance imaging (MRI) scans versus those with focal or circumscribed frontal lobe atrophy (F-type). METHODS: In total, 94 MRI scans (74 scans from bvFTD and 20 scans from age-matched normal controls) were classified into 35 D- and 39 F-type bvFTD cases based on an axial MRI visual rating scale. We compared baseline clinical characteristics, progression in motor and cognitive symptoms, and survival times between D- and F-types. Survival analyses were performed for 62 of the 74 patients. RESULTS: While D-type performed better on neuropsychological tests than F-type at baseline, D-type had higher baseline scores on the Unified Parkinson's Disease Rating Scale (UPDRS) Part III. Evaluations of motor progression showed that the disease duration with motor symptoms was shorter in D-type than F-type. Moreover, the survival time was shorter in D-type (6.9 years) than F-type (9.4 years). Cox regression analyses revealed that a high UPDRS Part III score at baseline contributed to an increased risk of mortality, regardless of the pattern of atrophy. CONCLUSIONS: The prognosis is worse for D-type than for those with F-type. Shorter survival in D-type may be associated with the earlier appearance of motor symptoms.
Atrophy*
;
Disease Progression
;
Frontal Lobe
;
Frontotemporal Dementia*
;
Frontotemporal Lobar Degeneration
;
Humans
;
Magnetic Resonance Imaging
;
Mortality
;
Neurobehavioral Manifestations
;
Neuropsychological Tests
;
Parkinson Disease
;
Prognosis*